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Although the concept of Syndrome X was introduced in the Banting Medal address of 1988 (Reaven, 1988), the notion that
led to its genesis had started approximately 50 years earlier. In this short history, an attempt will be made to trace the
two paths of scientific discovery that were formally merged in New Orleans in 1988 to form the scientific foundation of
Syndrome X. In addition, the developments in the last 16 years that have led from the notion of Syndrome X to the broader
concept of an Insulin Resistance Syndrome (IRS) will be briefly summarized.The two faces of diabetes mellitus
In the spring of 1939, just before the beginning of World War
II, Himsworth summarized in the Goulstonion Lectures on the
“Mechanism of Diabetes Mellitus” to the Royal College of
Physicians of London the results of the work that he and his
colleagues had initiated in 1936. The substance of these lec-
tures was later published in The Lancet (Himsworth, 1939a,
1939b, 1939c, 1939d) and offered a startlingly modern view of
the pathophysiology of diabetes mellitus. Specifically, Hims-
worth concluded “diabetes mellitus is a disease in which the
essential lesion is a diminished ability of the tissue to utilize
glucose. The high blood sugar is a controlled and compensa-
tory phenomenon, the object of which is to facilitate the utiliza-
tion of glucose by the tissues.” He went on to question the
general belief that “all cases of human diabetes could be ex-
plained by deficiency of insulin,” and raised the possibility that
“a state of diabetes might result from inefficient action of insu-
lin as well as from a lack of insulin.”
Based upon the general principles outlined above, Hims-
worth reviewed the results of a series of simple, but elegant,
experiments aimed at understanding why hyperglycemia oc-
curred in patients with diabetes. Summarizing these findings,
he proposed “the diminished ability of the tissues to utilize glu-
cose is referable either to a deficiency of insulin or to insensitiv-
ity to insulin, although it is possible that both factors may oper-
ate simultaneously.” Given this distinction, he concluded by
pointing out that diabetes should be subdivided into two cate-
gories “according to which of these disorders predominates
into insulin-sensitive and insulin-insensitive types.” Himsworth
also differentiated the two types on clinical grounds, pointing
out that “insulin-sensitive diabetes, which is thought to be due
to a deficiency of insulin, tends to be severe,” whereas insulin-
insensitive diabetes, “due not to a lack of insulin but to insensi-
tivity of insulin, is generally less severe.”
World War II essentially ended Himsworth’s experimental
studies of the relationship between insulin resistance and dia-
betes mellitus, but in 1949 he delivered the Oliver-Shappey lec-
tures to the Royal College of Physicians (Himsworth, 1949),
concluding that “it appears we should accustom ourselves to
the idea that a primary deficiency of insulin is only one, andCELL METABOLISM : JANUARY 2005 · VOL. 1 · COPYRIGHT © 2005 ELthen not the commonest, cause of the diabetes syndrome.” In
retrospect, it is difficult to comprehend that the view of dia-
betes outlined by Himsworth in the Goulstonion Lectures ante-
dated by approximately 40 years the imprimatur given by the
National Diabetes Data Group to a remarkably similar division
of patients with diabetes mellitus into two major subtypes (Na-
tional Diabetes Data Group, 1979).
Insulin resistance and type 2 diabetes
To support the suggestion by Himsworth that not all diabetes
was secondary to absolute insulin deficiency, it was necessary
to establish the fact that circulating insulin was present in those
patients classified by Himsworth as being insulin insensitive. In
an effort to address this issue, bioassays were developed to
estimate plasma insulin-like activity, and results were published
indicating that normal, or greater than normal levels of insulin-
like activity were present in patients with what was then re-
ferred to as maturity-onset diabetes (Bornstein and Lawrence,
1951; Vallance-Owen et al., 1955). However, these methods for
estimating plasma insulin concentrations were far from ideal:
as experience with the different methods increased, the situa-
tion became less clear, and there was continuing controversy
as to what actually were the circulating plasma insulin concen-
trations in patients with diabetes mellitus. This uncertainty
ended abruptly with the publication of an immunoassay study
of endogenous plasma insulin in man (Yalow and Berson,
1960). In this groundbreaking work, Yalow and Berson de-
scribed an immunological method for measuring insulin that
combined specificity with the degree of sensitivity needed to
measure the minute concentrations of insulin present in the cir-
culation. Using this new method to compare plasma immuno-
reactive insulin levels in normal subjects to those of patients
with maturity-onset diabetes, they found that the insulin levels
were on the average higher in the diabetic patients. On the
basis of these results they concluded “that the tissues of the
maturity-onset diabetic do not respond to his insulin as well as
the tissues of the nondiabetic subject respond to his insulin.”
Or, to use Himsworth’s terminology, patients with this form of
diabetes were “insulin insensitive.”
Although the results of the initial publication by Yalow andSEVIER INC. DOI:10.1016/j.cmet.2004.12.001 9
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it became apparent that the relationship between plasma glu-
cose and insulin concentrations in patients with type 2 diabe-
tes was not a simple one, and that plasma insulin responses to
oral glucose could not be simply divided into two categories—
absent or present. Specifically, in individuals with relatively mi-
nor elevations of fasting plasma glucose concentration, plasma
insulin responses to oral glucose in absolute terms were equal
to or greater than normal, but, with increasing degrees of glu-
cose intolerance, and the appearance of significant fasting hy-
perglycemia, the plasma insulin response became attenuated,
and with severe fasting hyperglycemia, the insulin response
was less than in normal control subjects (Buchanan and
McKiddie, 1967; Chiles and Tzagournis, 1970; Hales and
Randle, 1963; Reaven and Miller, 1968).
Furthermore, the observation that essentially no patients
with type 2 diabetes were as insulin deficient as those with
type I diabetes was not necessarily translated into the belief
that resistance to insulin-mediated glucose disposal was pre-
sent in patients with type 2 diabetes. Thus, at various times it
has been argued that hyperglycemia in patients with type 2
diabetes had nothing to do with insulin resistance but was to-
tally a function of (1) delay in rate of appearance of insulin in
plasma; (2) lack of “appropriateness” in the pancreatic β cell
response to glucose (the absolute increase in plasma insulin
was not high enough given the coexisting plasma glucose con-
centration); or (3) the preferential secretion of proinsulin (Melani
et al., 1970; Perley and Kipnis, 1966; Seltzer et al., 1967). Fur-
ther confounding the situation was the fact that a variety of
different insulinogenic stimuli were used to compare the
plasma insulin response of various experimental groups, in-
cluding oral glucose, intravenous glucose, amino acids, gluca-
gon, sulfonylurea compounds, and mixed meals.
It became apparent that the controversy as to whether or not
insulin resistance existed in patients with type 2 diabetes was
not going to be solved by philosophical arguments as to the
meaning of plasma insulin measurements. Instead, it was nec-
essary to develop an experimental approach that would quan-
tify in an unambiguous manner the ability of an individual to
dispose of fixed glucose load under the influence of identical
insulin stimuli during steady-state conditions (Shen et al.,
1970). This was accomplished by infusing subjects for 180 min
with constant amounts of insulin, glucose, epinephrine, and
propranolol. Steady-state plasma concentrations of insulin and
glucose were achieved within 90 min after the start of the infu-
sion and were measured every 10 min during the final 30 min
of the study. This approach was based upon the ability of epi-
nephrine and propranolol to suppress endogenous insulin
secretion and inhibit hepatic glucose output. Under these con-
ditions, it was possible to assess the ability of plasma insulin
concentrations, similar in terms of both quantity and quality, to
promote the disposal of comparable glucose loads in a variety
of subjects. With this experimental design, the height of the
steady-state plasma glucose concentration (SSPG) is a direct
reflection of a subject’s overall efficiency of insulin-mediated
glucose disposal. Once this approach was validated, it was
possible over the next few years to demonstrate that patients
with impaired glucose tolerance and type 2 diabetes, as a
group, were insulin resistant (Ginsberg et al., 1974, 1975; Shen
et al., 1970). Subsequently, similar results were obtained as to10the existence of insulin resistance in patients with type 2 diabe-
tes when measurements of insulin-mediated glucose disposal
were made with the euglycemic clamp technique (DeFronzo et
al., 1979; Kolterman et al., 1981; Reaven, 1983). As a result, a
consensus was soon reached, approximately 40 years after the
initial studies of Himsworth, that a defect in the ability of insulin
to increase tissue utilization of glucose was present in the vast
majority of patients with type 2 diabetes (Reaven, 1983).
Cross-sectional studies published shortly after introduction
of the radioimmunoassay for insulin were consistent with the
hypothesis that patients with type 2 diabetes, as a group, were
insulin resistant, and that hyperglycemia supervened in these
individuals when the pancreatic β cell was no longer capable
of maintaining the degree of compensatory hyperinsulinemia
needed to overcome the defect in insulin action (Buchanan and
McKiddie, 1967; Chiles and Tzagournis, 1970; Hales and
Randle, 1963; Reaven and Miller, 1968). Once it had been
established that resistance to insulin-mediated glucose dis-
posal was a characteristic of patients with type 2 diabetes
(Reaven, 1983), longitudinal studies were initiated to test the
hypothesis that this defect antedated the development of hy-
perglycemia in individuals at increased risk to develop type 2
diabetes. Evidence in support of this formulation was soon
available from the results of prospective studies showing in
nondiabetic individuals that hyperinsulinemia, as a surrogate
marker for insulin resistance, predicted the development of
type 2 diabetes (Haffner et al., 1990; Saad et al., 1989; Sicree
et al., 1987). The story initiated by Himsworth was completed
with publication of the results of prospective studies showing
that the best predictor of the development of type 2 diabetes
in nondiabetic individuals was the presence of insulin resis-
tance and hyperinsulinemia at baseline (Lillioja et al., 1993;
Warram et al., 1990).
Perhaps the most fitting way to end this section is with the
following quote from a brilliant paper by Himsworth and Kerr,
published approximately 65 years ago (Himsworth and Kerr,
1939):
On the whole the insulin-sensitive diabetics tend to be youn-
ger, thin, to have a normal blood pressure and healthy arter-
ies; in them the disease is sudden and severe at onset; they
easily develop ketosis and react to a slight excess of insulin
with a hypoglycaemic attack. The insulin-insensitive diabet-
ics on the other hand tend to be older, obese, to have hyper-
tension and to exhibit arteriosclerosis; in them the onset of
the disease is insidious; they rarely develop ketosis and can
tolerate over-dosage of insulin without showing symptoms
of hypoglycaemia.
Insulin resistance, compensatory hyperinsulinemia,
and cardiovascular disease (CVD): Syndrome X
The notion that resistance to insulin-mediated glucose disposal
and compensatory hyperinsulinemia could play a role in CVD
began with an attempt to formulate a general hypothesis to
explain the following four apparently disparate observations.
(1) In the late 1950s, Albrink and Mann demonstrated that
hypercholesterolemia was not the only abnormality of lipid me-
tabolism associated with CVD risk, and that hypertriglyceride-
mia was as common, if not more so, in patients with manifest
CVD (Albrink and Mann, 1958a, 1958b).CELL METABOLISM : JANUARY 2005
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that hypertriglyceridemia in patients with “essential lipemia”
could be divided on the basis of their response to formula diets
into two forms: carbohydrate (CHO)-induced and fat-induced
lipemia (Ahrens et al., 1961). Furthermore, and contrary to con-
ventional wisdom, they pointed out that the vast majority of
hypertriglyceridemic individuals had the CHO-induced variety.
(3) Once the insulin immunoassay was introduced, it became
clear that a significant number of individuals with relatively mi-
nor degrees of glucose intolerance had significantly elevated
plasma insulin concentrations (Yalow and Berson, 1960).
(4) Evidence was published showing that individuals with a
documented myocardial infarction, studied several months af-
ter the acute coronary event, at a time when they were asymp-
tomatic, were somewhat glucose intolerant and hypertriglyceri-
demic when compared to an appropriately matched control
group (Reaven et al., 1963).
Based upon the four findings outlined above, the following
schema was formulated in an attempt to tie them all together.
It was argued that resistance to insulin-mediated glucose dis-
posal is frequently present in apparently healthy individuals,
but that the majority of insulin-resistant individuals can secrete
enough insulin to compensate for their defect in insulin action,
thereby preventing frank deterioration of glucose tolerance.
Unfortunately, the compensatory hyperinsulinemia in insulin-
resistant persons acts on the liver to stimulate very low density
lipoprotein triglyceride (VLDL-TG) synthesis and secretion,
leading to hypertriglyceridemia and increased CVD risk. The
untoward effects of daylong hyperinsulinemia in insulin-resis-
tant/hypertriglyceridemic individuals are accentuated in re-
sponse to low-fat/high-carbohydrate diets, leading to even fur-
ther increases in plasma TG concentration.
The necessary first step in evaluating the hypothesis outlined
above was to develop an isotopic method to quantify VLDL-
TG secretion rate (Farquhar et al., 1965). Once this was accom-
plished, it was shown that the greater the VLDL-TG secretion
rate, the higher the plasma TG concentration (Reaven et al.,
1965). The next step was the demonstration that the higher
the plasma insulin response to meals, the greater the VLDL-
TG secretion rate, and the higher the plasma TG concentration
(Reaven et al., 1967). During this period, further evidence was
provided in support of the earlier findings of the existence of
CHO-induced lipemia (Ahrens et al., 1961), and, more impor-
tantly, to demonstrate that the dietary-induced increase in
plasma TG concentration was highly correlated with the asso-
ciated elevation of plasma insulin concentrations that occur in
response to low-fat/high-CHO diets (Farquhar et al., 1966). Fi-
nally, once the method to quantify insulin-mediated glucose
disposal was available, it was shown that the more insulin re-
sistant the individual, the higher was the plasma insulin re-
sponse to meals, the greater the VLDL-TG secretion rate, and
the more elevated the plasma TG concentration (Olefsky et
al., 1974).
Table 1 lists the components of Syndrome X as defined inTable 1. Syndrome X—Increased risk of cardiovascular disease
Insulin resistance
Compensatory hyperinsulinemia
Varying degrees of glucose tolerance
[ Plasma TG concentration
Y Plasma HDL cholesterol concentrationCELL METABOLISM : JANUARY 20051988, and it can be seen that the major elements had been
shown to exist by 1974. The importance of a low high-density
lipoprotein cholesterol (HDL-C) concentration as a CVD risk
factor, and the frequency with which it was associated with an
elevated TG concentration, became clear over the next few
years (Castelli et al., 1986; Miller and Miller, 1975; Reaven,
1988).
The possibility that essential hypertension was also related
to insulin resistance/compensatory hyperinsulinemia should
have been appreciated following the report that 19 individuals
with essential hypertension had significantly higher plasma in-
sulin concentrations than a control population (Welborn et al.,
1966). However, approximately 20 years elapsed before there
was confirmation of the initial observation that hyperinsuli-
nemia was present in patients with essential hypertension (Lu-
cas et al., 1985; Modan et al., 1985). Given these findings, and
the earlier demonstration that glucose intolerance occurred
with greater frequency in patients with essential hypertension
(Jarret et al., 1978), it was not surprising that evidence was
soon published showing that the prevalence of resistance to
insulin-mediated glucose uptake was also increased in patients
with this clinical syndrome (Ferrannini et al., 1987; Shen et al.,
1988). The fact that patients with essential hypertension, as a
group, were insulin resistant, hyperinsulinemic, and somewhat
glucose intolerant not only suggested that essential hyperten-
sion be added to the abnormalities listed in Table 1 but also
provided further support for the notion that all of these changes
were likely to cluster within the same individual. Direct evidence
in support of the concept of Syndrome X was soon provided by
the results of a population-based study, in which apparently heal-
thy individuals were stratified into hyperinsulinemic and normoin-
sulinemic groups (as surrogate measures of insulin resistance
and insulin sensitivity), showing that the hyperinsulinemic (in-
sulin-resistant) individuals were somewhat glucose intolerant,
with mildly elevated blood pressure, and had higher plasma TG
and lower HDL-C concentrations (Zavaroni et al., 1989).
From Syndrome X to the Insulin Resistance Syndrome
By 1988, there was widespread recognition that (1) being insu-
lin resistant increased the risk of developing type 2 diabetes;
(2) most patients with type 2 diabetes were insulin resistant;
and (3) type 2 diabetes occurred when insulin-resistant individ-
uals could not maintain the degree of hyperinsulinemia neces-
sary to maintain normal glucose tolerance. The fact that most
insulin-resistant individuals continued to sustain the degree of
compensatory hyperinsulinemia needed to prevent gross de-
compensation of glucose tolerance, and were thereby at
increased CVD risk, was not well appreciated and is why the
concept of Syndrome X as shown in Table 1 was introduced.
There were two reasons for designating the abnormalities
listed in Table 1 as Syndrome X. In the first place, it was based
on the use of the algebraic term for the unknown (let X equal
the unknown) to emphasize that the importance of insulin resis-
tance and its associated abnormalities as CVD risk factors was
largely unrecognized. Secondly, in order to draw attention to
the CVD risk factors associated with insulin resistance/hyperin-
sulinemia, and avoid distractions concerning the pathogenesis
of each of the components seen in Table 1, it seemed best to
use a nonspecific descriptor term. However, since the intro-
duction of Syndrome X, considerable new information has11
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ease. These findings, in addition to solidifying the role of insulin
resistance as increasing CVD risk, have greatly expanded the
abnormalities and clinical syndromes more likely to occur in
insulin-resistant individuals, as shown in Table 2. It is not pos-
sible to review the experimental data that supports the infor-
mation in Table 2, but a detailed discussion of these issues can
be found in a recently published review (Reaven, 2004). As a
result of all the information now available, the relatively simple
formulation shown in Table 1 is no longer appropriate, and the
modification illustrated in Figure 1 is a more accurate depiction
of the current situation. Finally, as a consequence of the experi-
mental findings since the introduction of Syndrome X, it seems
reasonable that this term be replaced with the notion of the
Insulin Resistance Syndrome (IRS), a pathophysiological con-
struct under which the abnormalities and clinical syndromes
more likely to occur in insulin-resistant/hyperinsulinemic in-
dividuals that do not develop type 2 diabetes can be appropri-
ately subsumed.
It must be emphasized that insulin resistance is not a dis-
ease but rather a description of a physiological state. An insu-
lin-resistant individual has a greater likelihood of developing
the closely related abnormalities and associated clinical syn-
dromes shown in Table 2. The IRS is a designation to describe
the abnormalities and clinical syndromes more likely to occur
in association with insulin resistance. It must be clearly under-Table 2. The Insulin Resistance Syndrome
Metabolic abnormalities associated with insulin resistance/hyperinsulinemia
Some degree of glucose intolerance
Impaired fasting glucose
Impaired glucose tolerance
Dyslipidemia
[ Triglycerides
Y HDL-C
Y LDL-particle diameter (small, dense LDL-particles)
[ Postprandial accumulation of TG-rich lipoproteins
Endothelial dysfunction
[ Mononuclear cell adhesion
[ Plasma concentration of cellular adhesion molecules
[ Plasma concentration of asymmetric dimethylarginine
Y Endothelial-dependent vasodilatation
Procoagulant factors
[ Plasminogen activator inhibitor-1
[ Fibrinogen
Hemodynamic changes
[ Sympathetic nervous system activity
[ Renal sodium retention
Markers of inflammation
[ C-reactive protein, WBC, etc.
Abnormal uric acid metabolism
[ Plasma uric acid concentration
Y Renal uric acid clearance
Increased testosterone secretion (ovary)
Sleep disordered breathing
Clinical manifestations of insulin resistance
Type 2 diabetes
Essential hypertension
Cardiovascular disease
Polycystic ovary syndrome
Nonalcoholic fatty liver disease
Certain forms of cancer
Sleep apnea12Figure 1. A schematic description of the clinical syndromes that occur more
commonly in association with insulin resistance (current clinical manifestations
of the Insulin resistance Syndrome)
Insulin resistance is depicted as leading to type 2 diabetes, as well as a number
of other syndromes, associated with the defect in insulin action, in which the
magnitude of the compensatory hyperinsulinemia prevents loss of glucose ho-
meostasis. It should be noted that while being insulin resistant may lead to type
2 diabetes, the microangiopathic complications only occur when frank hypergly-
cemia is present. The Insulin Resistance Syndrome is used to provide a physio-
logical framework with which to help understand the link between insulin resis-
tance/compensatory hyperinsulinemia and the abnormalities and clinical
syndromes listed in Table 2.
PCOS = polycystic ovary syndrome; NAFLD = nonalcoholic fatty liver disease;
CVD = cardiovascular disease.stood that any individual component of the IRS can occur in
the absence of insulin resistance, and being insulin resistant
does not necessarily lead to any of the manifestations of the
IRS. Of great importance is the fact that not all tissues in any
given individual are equally insulin resistant, and many of the
manifestations of the IRS are secondary to the compensatory
hyperinsulinemia acting on normally insulin-sensitive tissues.
Conclusion
Approximately 65 years have elapsed since Himsworth first
proposed that patients with diabetes mellitus could be divided
into two categories—insulin sensitive and insulin insensitive.
His focus was on the role of insulin insensitivity in the patho-
genesis of hyperglycemia, and it is now clear that this was sim-
ply the first of what is an ever-growing list of clinical syndromes
associated with insulin resistance. Given that insulin action
varies more than 6-fold in apparently healthy individuals (Yeni-
Komshian et al., 2000), and that differences in level of adiposity
(25%) and physical fitness (25%) account for approximately
50% of this variability (Bogardus et al., 1985), it should be obvi-
ous that as the world becomes more obese, and less active,CELL METABOLISM : JANUARY 2005
H I S T O R I C A L P E R S P E C T I V Ethe problems associated with the IRS are the plague of the
21st century.
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